MYOV - Myovant Pfizer's relugolix combo shows durable efficacy in uterine fibroids

Myovant Sciences (MYOV) and Pfizer (PFE) announces publication of Phase 3 LIBERTY 1 and LIBERTY 2 studies of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids in the New England Journal of Medicine.LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline, compared with 18.9% and 14.7% of women in the placebo groups.Bone mineral density was maintained at levels comparable to placebo.Six of seven key secondary endpoints were achieved at week 24, including reduction of pain. A seventh key secondary endpoint for reduction in fibroid volume was not achieved in either study.Myovant previously announced results from LIBERTY long-term extension study in February 2020.

For further details see:

Myovant, Pfizer's relugolix combo shows durable efficacy in uterine fibroids